Short Interest in Synthetic Biologics Inc (NYSEAMERICAN:SYN) Rises By 66.8%

Synthetic Biologics Inc (NYSEAMERICAN:SYN) saw a large increase in short interest in the month of October. As of October 31st, there was short interest totalling 172,100 shares, an increase of 66.8% from the September 30th total of 103,200 shares. Based on an average daily volume of 83,300 shares, the days-to-cover ratio is presently 2.1 days. Currently, 1.1% of the shares of the company are sold short.

NYSEAMERICAN:SYN opened at $0.43 on Thursday. Synthetic Biologics has a 52-week low of $0.37 and a 52-week high of $0.91.

Synthetic Biologics (NYSEAMERICAN:SYN) last posted its quarterly earnings data on Monday, November 4th. The company reported ($0.31) earnings per share (EPS) for the quarter.

An institutional investor recently bought a new position in Synthetic Biologics stock. Wedbush Securities Inc. acquired a new position in shares of Synthetic Biologics Inc (NYSEAMERICAN:SYN) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 97,957 shares of the company’s stock, valued at approximately $54,000. Wedbush Securities Inc. owned 0.58% of Synthetic Biologics as of its most recent filing with the Securities and Exchange Commission.

Synthetic Biologics Company Profile

Synthetic Biologics, Inc, a clinical stage company, focuses developing therapeutics designed to preserve the microbiome to protect and restore the health of patients in the United States. Its lead product candidates include SYN-004 that is in Phase III clinical trial designed to protect the gut microbiome from the effects of commonly used intravenous beta-lactam antibiotics in gastrointestinal tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease in allogeneic hematopoietic cell transplant recipients.

Further Reading: Dividend Yield

Receive News & Ratings for Synthetic Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics and related companies with's FREE daily email newsletter.